| Patient | Frédéric Chopin |
|---|---|
| Date of birth | 1998-03-01 |
| Identifiers | MRN HR-NI020-SYN; SSN (made up) 000-20-8845 |
| Document date | 2026-07-21 |
| Author | Matthias Lindqvist, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
End-of-treatment review after 119 doses. [S]
Mr. Chopin returns five days after his 119th and last dose. He took every dose on his video calls, 56 in the intensive phase and 63 in the continuation phase, finishing in 17 weeks. The two-month culture grew nothing, so he has two consecutive negative cultures. The cold he had in June cleared within ten days. He has no cough, sputum, fever, night sweats, or blood, and he weighs 55.0 kg, 6.5 kg more than at diagnosis. He had no tendon pain or tingling at any point. Between the sick visit and today there was no clinic review; the health department nurse asked about symptoms and side effects on every video call. He is teaching his full schedule of fifteen students and has started practicing for a small recital. [S]
| Element | Detail |
|---|---|
| Treatment | 119 of 119 doses observed, completed in 17 weeks |
| Cultures | Third-week and two-month cultures negative |
| Weight | 55.0 kg, up 6.5 kg since diagnosis |
| Work | Teaching fifteen students a week |
| System | Result | Finding |
|---|---|---|
| Respiratory | Negative | No cough, sputum, hemoptysis, or breathlessness |
| Constitutional | Negative | No fever, night sweats, or weight loss |
| Musculoskeletal | Negative | No tendon pain |
| Neurological | Negative | No numbness or tingling |
| Psychiatric | Negative | Mood good; PHQ-9 3; no thoughts of suicide or self-harm |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Rifapentine 150 mg tablets, eight tablets (1200 mg) daily with food | 1200 mg once daily with a meal by video-observed therapy with the health department, seven days a week, for 17 weeks (119 doses) | Oral route | 2026-03-20 to 2026-07-16 | completed | S |
| Moxifloxacin 400 mg tablet, one tablet daily | 400 mg once daily with the other drugs by video-observed therapy with the health department, seven days a week, for 17 weeks; no mineral supplements within 4 hours before or 8 hours after | Oral route | 2026-03-20 to 2026-07-16 | completed | S |
| Isoniazid 300 mg tablet, one tablet daily | 300 mg once daily by video-observed therapy with the health department, seven days a week, for 17 weeks | Oral route | 2026-03-20 to 2026-07-16 | completed | S |
| Pyrazinamide 500 mg tablets, two tablets (1000 mg) daily | 1000 mg once daily by video-observed therapy with the health department, seven days a week, for the eight-week intensive phase (weight band 40 to under 55 kg) | Oral route | 2026-03-20 to 2026-05-14 | completed | S |
| Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily | 50 mg once daily with isoniazid | Oral route | 2026-03-20 to 2026-07-16 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-07-21 | Body height | 170 | cm | S |
| 2026-07-21 | Body weight | 55 | kg | S |
| 2026-07-21 | Body mass index (BMI) [Ratio] | 19 | kg/m2 | S |
| 2026-07-21 | Systolic blood pressure | 110 | mm[Hg] | S |
| 2026-07-21 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 2026-07-21 | Heart rate | 72 | /min | S |
| 2026-07-21 | Respiratory rate | 14 | /min | S |
| 2026-07-21 | Body temperature | 36.6 | Cel | S |
| 2026-07-21 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-07-21 | Hemoglobin [Mass/volume] in Blood | 14.1 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 2026-07-21 | Albumin [Mass/volume] in Serum or Plasma | 4 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-07-21 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 7-56 U/L | Normal | S |
| 2026-07-21 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S |
Vital signs recorded on 2026-07-21; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 55.0 kg, BMI 19.0 |
| Respiratory | Clear, with no crackles |
| Abdomen | Liver not enlarged |
| Musculoskeletal | Tendons non-tender |
| Neurological | Normal sensation and fine finger movements |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Cough for about three months, blood-streaked sputum for two weeks, night sweats, and weight loss of about 6 kg in a man of 28, with a right upper lobe cavity on chest X-ray and CT: suspected pulmonary tuberculosis; home airborne isolation and three sputum samples for acid-fast smear, nucleic acid amplification, and culture | resolved | confirmed | R04.2 | S — Synthetic presenting problem linked to his documented chronic cough and hemoptysis; superseded by the diagnosis at the second visit. |
| Pulmonary tuberculosis of the right upper lobe, cavitary and sputum smear-positive, confirmed by nucleic acid amplification without rifampin resistance | active | confirmed | A15.0 | S — Synthetic modern coding of his documented tuberculosis, chosen over the disputed genetic and cardiac alternatives; the cavity and all bacteriology are synthetic. |
| Moderate protein-calorie malnutrition: BMI 16.8, about 11 percent weight loss in three months, and albumin 3.2 g/dL | resolved | confirmed | E44.0 | S — Synthetic nutrition diagnosis anchored to his documented frailty and exhaustion. |
| Acute viral upper respiratory infection during the continuation phase of tuberculosis treatment; resolved | resolved | confirmed | J06.9 | S — Synthetic intercurrent illness chosen to teach how to tell a cold from tuberculosis treatment failure, and moxifloxacin interactions with cold remedies; it does not echo a documented illness. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Symptom review: cough, sputum, hemoptysis, fever, night sweats | Every visit | Completed today | No symptoms |
| Examination | Weight, with the pyrazinamide dose checked against the weight band | Monthly | Completed today | 55.0 kg |
| Medication safety | Adverse effects: hepatitis symptoms, tendon pain, numbness or tingling, rash, nausea, orange body fluids | Every visit | Completed today | None at any visit or video call |
| Examination | Clinical review (adherence, symptoms, adverse effects, weight) | At least monthly during treatment | Deferred | No clinic review between the sick visit in early June and today, about six weeks, because the schedule went from the end of the intensive phase to the end of treatment. The nurse reviewed symptoms and side effects on every video call, and today's examination, weight, and tests are normal, so no harm is evident. Corrective action: monthly clinic reviews booked at the start of treatment for every patient on the four-month regimen |
| Laboratory | Liver tests (ALT, AST, bilirubin) | Baseline; repeat for symptoms or risk factors (here at two to three weeks, for low weight and albumin) | Completed today | ALT 22 U/L at the end of treatment |
| Laboratory | Hemoglobin and albumin | At the end of treatment when low at baseline | Completed today | Hemoglobin 14.1 g/dL; albumin 4.0 g/dL |
| Laboratory | Sputum acid-fast smear and culture | Baseline, then monthly until two consecutive cultures are negative | Completed today | Two consecutive negative cultures (third week and two months); no further sputum needed |
| Laboratory | Two-month sputum culture | At the end of the intensive phase; a positive result needs evaluation and repeat susceptibility testing | Completed today | No growth |
| Imaging | Chest X-ray | Baseline; at two months only if baseline cultures were negative; end of treatment optional | Completed today | Cavity closed; small area of right upper lobe scarring |
| Medication safety | Doses observed and the completion clock (56 doses within 70 days, 63 within 84 days, 119 within five months) | Every visit | Completed today | 119 doses in 17 weeks, within five months |
| Referral | Notification of treatment completion | At the end of treatment | Completed today | Sent to the health department today |
| Survey | Depression screen (PHQ-9) | At diagnosis, at two months, and at the end of treatment | Completed today | 3, item 9 scored 0 |
| Self-management | Nutrition: dietitian, intake, supplement drinks | Every visit until weight is restored | Completed today | Weight goal met; supplements stopped |
| Referral | Infectious diseases review | At diagnosis, at two months, and at the end of treatment | Completed today | Results reviewed by message; no routine follow-up |
Goal progress:
Guideline basis: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022 (2022); An official ATS statement: hepatotoxicity of antituberculosis therapy (2006); Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005); Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition) (2012); Depression and Suicide Risk in Adults: Screening (2023)
Follow-up: Adult preventive visit in about two months. Same-day visit for symptoms of relapse. Next scheduled visit 2026-09-15: adult preventive visit. [S]